<DOC>
	<DOCNO>NCT01836705</DOCNO>
	<brief_summary>Primary Objective : - To assess effect SAR302503 ( 500 mg ) administer 14-day repeated dos QTcF interval compare 1-day placebo patient advance solid tumor . Secondary Objectives : - To assess effect SAR302503 administer 14-day repeated dos heart rate ( HR ) , QT , QTcB , QTcN , PR QRS compare placebo . - To assess clinical laboratory safety SAR302503 - To document plasma concentration SAR302503 time ECG investigation . - To explore Pharmacokinetic/Pharmacodynamic relationship SAR302503 concentration QTcF - To explore antitumor activity</brief_summary>
	<brief_title>Effect SAR302503 ECG Activity Patients With Solid Tumors</brief_title>
	<detailed_description>Total 7-10 week progress Segment 2 . Segment 2 additional 28-day cycle .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm advanced solid malignancy metastatic unresectable , standard curative measure exist Exclusion criterion : Prior history torsades de pointe , congenital long QT syndrome . Conditions screen ECG repolarization difficult interpret , show significant abnormality . This include , limited : High degree atrioventricular ( AV ) block , pacemaker , atrial fibrillation flutter Screening ECG QTc B QTc F ≥480 msec ( within 8 day Day1 ) Significant hypokalemia screening ( K+ &lt; 3.5 mmol/L ) ( within 8 day Day1 ) Significant hypomagnesemia screen inclusion ( Mg++ &lt; 0.7 mmol/L ) ( within 8 day Day 1 ) Patient receives ( discontinue ) , schedule receive , concomitant treatment know carry risk QT prolongation torsade de pointe 2 week Day 1 duration Segment 1 Absence completion prior chemotherapy , biological therapy , hormonal therapy , target noncytotoxic therapy ≥3 week ; radiotherapy ≥2 week prior inclusion . Patients uncontrolled brain metastasis primary brain tumor . Patients brain metastasis consider eligible patient receive radiation therapy brain metastasis within 2 week enrollment stable dose steroid ≥ 2 week . Participation study investigational agent ( drug , biologic , device ) within 30 day prior initiation study drug , unless nontreatment phase . Anticipation need major surgical procedure radiation therapy study treatment . Concurrent treatment another clinical trial cancer therapy include chemotherapy , biological therapy , hormonal therapy , radiotherapy , chemoembolization , cryotherapy , target noncytotoxic therapy patient plan receive treatment study . Inadequate organ function define : Absolute neutrophil count ( ANC ) &lt; 1.5 X 10^9/L Platelet count &lt; 100 X 10^9/L Hemoglobin : &lt; 9 g/dL Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) Serum amylase lipase &gt; 1.5 x ULN Total bilirubin &gt; 1.5 x ULN Aspartate aminotransferase alanine aminotransferase ≥2.5 x ULN Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &gt; 2 study entry . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . Ongoing recent history ( within 3 month Day 1 Segment 1 ) clinically significant dysrrhythmia . Patients take beta blocker within 7 day Day 1 Segment 1 Segment 1 Other concurrent serious illness medical condition , include active infection HIV disease . Patients know active ( acute chronic ) Hepatitis A , B , C , hepatitis B C carrier . Prior history chronic liver disease . Patients history partial total gastrectomy , , opinion investigator , disorder would inhibit absorption oral medication . Any severe acute chronic medical , neurological , psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , Investigator 's opinion , would make patient inappropriate entry study . Contraindications palonosetron . Use drug herbal agent know least moderate inhibitor inducer CYP3A4 , sensitive CYP3A4 substrate , CYP3A4 substrate narrow therapeutic index , within 2 week Day 1 study . Concomitant treatment H2blockers allow within 7 day prior Day 1 Segment 1 entire study . Known hypersensitivity excipients IMP formulation . Pregnant lactate female Women childbearing potential , unless use effective contraception ( oral contraceptive ) study drug . Men partner woman childbearing potential , unless agree use effective contraception study drug The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>